延迟免疫调节改善小鼠持续炎症-免疫抑制-分解代谢综合征模型的免疫功能障碍
本研究在盲肠结扎穿刺(CLP)诱导的小鼠持续炎症-免疫抑制-分解代谢综合征模型中,于第4天后(急性反应消退时)给予粒细胞集落刺激因子、粒细胞-巨噬细胞集落刺激因子或抗程序性死亡配体1(PD-L1)抗体,评估逆转免疫功能障碍的效果。结果显示抗PD-L1治疗在改善免疫细胞数量、免疫功能、固有免疫细胞MHC-II和CD11b表达及T细胞干扰素γ产生方面优于粒细胞集落刺激因子和粒细胞-巨噬细胞集落刺激因子。然而,抗PD-L1治疗虽改善部分免疫参数,但在CLP后8天接种铜绿假单胞菌时未能实现有效细菌清除。尽管如此,抗PD-L1治疗组CLP小鼠生存率为100%,未治疗CLP小鼠为60%,且抗PD-L1治疗未影响生存。作者认为抗PD-L1治疗可能改善CLP后部分免疫功能障碍并提高继发细菌感染后的生存。
要点
- 在CLP小鼠模型第4天后给予抗PD-L1抗体,免疫细胞数量、功能、MHC-II和CD11b表达及T细胞干扰素γ产生改善优于粒细胞集落刺激因子和粒细胞-巨噬细胞集落刺激因子。
- 抗PD-L1治疗未改善CLP后8天接种铜绿假单胞菌的细菌清除。
- 抗PD-L1治疗组CLP小鼠生存率100%,未治疗CLP小鼠生存率60%,抗PD-L1未影响生存。
- 作者认为抗PD-L1治疗可能改善CLP后部分免疫功能障碍并提高继发细菌感染后生存。
适用人群与场景
- 小鼠持续炎症-免疫抑制-分解代谢综合征模型,通过盲肠结扎穿刺(CLP)诱导。
处置流程与药物剂量
- 在CLP后第4天,一旦典型急性反应开始消退,给予免疫调节剂:粒细胞集落刺激因子、粒细胞-巨噬细胞集落刺激因子或抗PD-L1抗体。
研究设计与关键结果
- 研究类型:动物实验(小鼠CLP模型);样本量原文未报告;人群:小鼠持续炎症-免疫抑制-分解代谢综合征模型;干预:CLP后第4天给予粒细胞集落刺激因子、粒细胞-巨噬细胞集落刺激因子或抗PD-L1抗体;对照:未治疗CLP小鼠;主要终点:免疫功能障碍逆转及生存。
- 抗PD-L1治疗在改善免疫细胞数量、免疫功能、固有免疫细胞MHC-II和CD11b表达及T细胞干扰素γ产生方面优于粒细胞集落刺激因子和粒细胞-巨噬细胞集落刺激因子。
- 抗PD-L1治疗未能在CLP后8天接种铜绿假单胞菌时实现有效细菌清除。
- 抗PD-L1治疗组CLP小鼠生存率100%,未治疗CLP小鼠生存率60%,抗PD-L1未影响生存。
证据类型、等级与局限
- 证据类型:动物实验(小鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为抗PD-L1治疗可能改善CLP后部分免疫功能障碍并提高继发细菌感染后的生存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Persistent Inflammation, Immunosuppression, and Catabolism Syndrome can occur after sepsis when there is an overwhelming systemic inflammatory response that leads to multiple organ dysfunction, significant morbidity, and chronic critical illness. Despite the increasing recognition of this clinical problem, there are no interventions that can reverse this response. This study aims to characterize the immune responses in a murine Persistent Inflammation, Immunosuppression, and Catabolism Syndrome model using cecal ligation and puncture (CLP) and assess the efficacy of various immunomodulatory agents, including granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and anti-programmed death-ligand 1 (PD-L1) antibody, in reversing the immune dysfunction when given after day 4, once the typical acute response to sepsis starts to subside. Our results showed that anti-PD-L1 therapy showed greater efficacy than granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in reversing immunosuppression post-CLP, as evidenced by improved immune cell numbers, immune function, MHC-II, and CD11b expression on innate immune cells, and interferon gamma production from T cells. However, while improving certain immune parameters, anti-PD-L1 treatment did not allow for effective bacterial clearance when the mice were inoculated with Pseudomonas aeruginosa 8 days after CLP. Interestingly, despite this decreased bacterial clearance, anti-PD-L1 therapy did not affect survival for CLP mice (100% survival) compared with untreated CLP mice (60% survival). These findings suggest that anti-PD-L1 therapy may improve some of the immune dysfunction seen after CLP and allow for improved survival following secondary bacterial infections.
参考来源
- Sengupta S, Alatrash N, Vaysburg D, et al. Delayed Immunomodulation Improves Immune Dysfunction in a Murine Model of Pics. Shock. 2026. PMID: 41670959. doi:10.1097/SHK.0000000000002803
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。